Singular Genomics Systems Stock In The News
| OMIC Stock | USD 0.40 0.01 2.56% |
The tone or emotional content of news articles related to Singular Genomics can affect its prices. Positive news sentiment can lead to an increase in demand for Singular Genomics' stock, while negative news sentiment can lead to a decrease in demand. Our overall analysis of Singular Genomics' news coverage and content from conventional and social sources shows investors' bearish mood towards Singular Genomics Systems. The specific impact of Singular Genomics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Singular Genomics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Singular Genomics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Singular Genomics Backtesting and Singular Genomics Hype Analysis.
Singular |
Singular Genomics Today Top News and Investor Outlook
Singular Genomics Systems Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Singular and other traded companies coverage. We help investors stay connected with Singular headlines for the 23rd of April to make an informed investment decision based on correlating the impacts of news items on Singular Stock performance. Please note that trading solely based on the Singular Genomics Systems hype is not for everyone as timely availability and quick action are needed to avoid losses.Singular Genomics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Singular earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Singular Genomics that are available to investors today. That information is available publicly through Singular media outlets and privately through word of mouth or via Singular internal channels. However, regardless of the origin, that massive amount of Singular data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Singular Genomics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Singular Genomics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Singular Genomics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Singular Genomics alpha.
Singular Largest EPS Surprises
Earnings surprises can significantly impact Singular Genomics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-09 | 2022-06-30 | -0.38 | -0.34 | 0.04 | 10 | ||
2022-03-02 | 2021-12-31 | -0.31 | -0.27 | 0.04 | 12 | ||
2023-11-14 | 2023-09-30 | -0.38 | -0.31 | 0.07 | 18 | ||
2022-11-07 | 2022-09-30 | -0.41 | -0.33 | 0.08 | 19 | ||
2023-03-02 | 2022-12-31 | -0.43 | -0.29 | 0.14 | 32 | ||
2021-08-03 | 2021-06-30 | -0.2 | -0.43 | -0.23 | 115 |
Singular Genomics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Singular Genomics Systems Stock. Current markets are strongly bullish. About 76% of major world exchanges and indexes are currently up. See today's market update for more information.
11th of April 2024
Singular Genomics Systems Trading Down 5.4 percent - Defense World at news.google.com
20th of March 2024
Singular Genomics Systems, Inc. Q4 2023 Earnings Call Transcript at insidermonkey.com
19th of March 2024
OMIC Stock Earnings Singular Genomics Sys Beats EPS, Beats Revenue for Q4 2023 at investorplace.com
15th of March 2024
Disposition of 14583 shares by Andrew Spaventa of Singular Genomics subject to Rule 16b-3 at MacroaxisInsider
1st of March 2024
Singular Genomics Systems Set to Announce Quarterly Earnings on Saturday at thelincolnianonline.com
5th of February 2024
Singular Genomics Showcases New G4X Spatial Sequencer at AGBT and Announces Significant Ad... at globenewswire.com
25th of January 2024
Singular Genomics Systems Price Target Lowered to 0.85 at The Goldman Sachs Group at thelincolnianonline.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Singular Genomics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Singular Genomics' short interest history, or implied volatility extrapolated from Singular Genomics options trading.
Check out Singular Genomics Backtesting and Singular Genomics Hype Analysis. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for Singular Stock analysis
When running Singular Genomics' price analysis, check to measure Singular Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Singular Genomics is operating at the current time. Most of Singular Genomics' value examination focuses on studying past and present price action to predict the probability of Singular Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Singular Genomics' price. Additionally, you may evaluate how the addition of Singular Genomics to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is Singular Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Singular Genomics. If investors know Singular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Singular Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.30) | Revenue Per Share 0.04 | Quarterly Revenue Growth 0.413 | Return On Assets (0.21) | Return On Equity (0.43) |
The market value of Singular Genomics Systems is measured differently than its book value, which is the value of Singular that is recorded on the company's balance sheet. Investors also form their own opinion of Singular Genomics' value that differs from its market value or its book value, called intrinsic value, which is Singular Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Singular Genomics' market value can be influenced by many factors that don't directly affect Singular Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Singular Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Singular Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Singular Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.